• Je něco špatně v tomto záznamu ?

The Histone Deacetylase Inhibitor Valproic Acid Exerts a Synergistic Cytotoxicity with the DNA-Damaging Drug Ellipticine in Neuroblastoma Cells

T. Cerna, J. Hrabeta, T. Eckschlager, E. Frei, HH. Schmeiser, VM. Arlt, M. Stiborová,

. 2018 ; 19 (1) : . [pub] 20180105

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc18033407

Neuroblastoma (NBL) originates from undifferentiated cells of the sympathetic nervous system. Chemotherapy is judged to be suitable for successful treatment of this disease. Here, the influence of histone deacetylase (HDAC) inhibitor valproate (VPA) combined with DNA-damaging chemotherapeutic, ellipticine, on UKF-NB-4 and SH-SY5Y neuroblastoma cells was investigated. Treatment of these cells with ellipticine in combination with VPA led to the synergism of their anticancer efficacy. The effect is more pronounced in the UKF-NB-4 cell line, the line with N-myc amplification, than in SH-SY5Y cells. This was associated with caspase-3-dependent induction of apoptosis in UKF-NB-4 cells. The increase in cytotoxicity of ellipticine in UKF-NB-4 by VPA is dictated by the sequence of drug administration; the increased cytotoxicity was seen only after either simultaneous exposure to these drugs or after pretreatment of cells with ellipticine before their treatment with VPA. The synergism of treatment of cells with VPA and ellipticine seems to be connected with increased acetylation of histones H3 and H4. Further, co-treatment of cells with ellipticine and VPA increased the formation of ellipticine-derived DNA adducts, which indicates an easier accessibility of ellipticine to DNA in cells by its co-treatment with VPA and also resulted in higher ellipticine cytotoxicity. The results are promising for in vivo studies and perhaps later for clinical studies of combined treatment of children suffering from high-risk NBL.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18033407
003      
CZ-PrNML
005      
20181010124914.0
007      
ta
008      
181008s2018 sz f 000 00|eng||
009      
AR
024    7_
$a 10.3390/ijms19010164 $2 doi
035    __
$a (PubMed)29304031
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Cerna, Tereza $u Department of Biochemistry, Faculty of Science, Charles University, Albertov 2030, CZ-128 43 Prague 2, Czech Republic. cernat10@natur.cuni.cz. Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, V Uvalu 84/1, CZ-150 06 Prague 5, Czech Republic. cernat10@natur.cuni.cz.
245    14
$a The Histone Deacetylase Inhibitor Valproic Acid Exerts a Synergistic Cytotoxicity with the DNA-Damaging Drug Ellipticine in Neuroblastoma Cells / $c T. Cerna, J. Hrabeta, T. Eckschlager, E. Frei, HH. Schmeiser, VM. Arlt, M. Stiborová,
520    9_
$a Neuroblastoma (NBL) originates from undifferentiated cells of the sympathetic nervous system. Chemotherapy is judged to be suitable for successful treatment of this disease. Here, the influence of histone deacetylase (HDAC) inhibitor valproate (VPA) combined with DNA-damaging chemotherapeutic, ellipticine, on UKF-NB-4 and SH-SY5Y neuroblastoma cells was investigated. Treatment of these cells with ellipticine in combination with VPA led to the synergism of their anticancer efficacy. The effect is more pronounced in the UKF-NB-4 cell line, the line with N-myc amplification, than in SH-SY5Y cells. This was associated with caspase-3-dependent induction of apoptosis in UKF-NB-4 cells. The increase in cytotoxicity of ellipticine in UKF-NB-4 by VPA is dictated by the sequence of drug administration; the increased cytotoxicity was seen only after either simultaneous exposure to these drugs or after pretreatment of cells with ellipticine before their treatment with VPA. The synergism of treatment of cells with VPA and ellipticine seems to be connected with increased acetylation of histones H3 and H4. Further, co-treatment of cells with ellipticine and VPA increased the formation of ellipticine-derived DNA adducts, which indicates an easier accessibility of ellipticine to DNA in cells by its co-treatment with VPA and also resulted in higher ellipticine cytotoxicity. The results are promising for in vivo studies and perhaps later for clinical studies of combined treatment of children suffering from high-risk NBL.
650    _2
$a apoptóza $7 D017209
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a synergismus léků $7 D004357
650    _2
$a elipticiny $x toxicita $7 D004611
650    _2
$a inhibitory histondeacetylas $x toxicita $7 D056572
650    _2
$a lidé $7 D006801
650    _2
$a mutageny $x toxicita $7 D009153
650    _2
$a neuroblastom $x metabolismus $7 D009447
650    _2
$a neurony $x účinky léků $x metabolismus $7 D009474
650    _2
$a kyselina valproová $x toxicita $7 D014635
655    _2
$a časopisecké články $7 D016428
700    1_
$a Hrabeta, Jan $u Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, V Uvalu 84/1, CZ-150 06 Prague 5, Czech Republic. janhrabeta@gmail.com.
700    1_
$a Eckschlager, Tomas $u Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, V Uvalu 84/1, CZ-150 06 Prague 5, Czech Republic. tomas.eckschlager@lfmtol.cuni.cz.
700    1_
$a Frei, Eva $u Department of Biochemistry, Faculty of Science, Charles University, Albertov 2030, CZ-128 43 Prague 2, Czech Republic. evafrei@t-online.de.
700    1_
$a Schmeiser, Heinz H $u Division of Radiopharmaceutical Chemistry, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany. h.schmeiser@dkfz-heidelberg.de.
700    1_
$a Arlt, Volker M $u Analytical and Environmental Sciences Division, MRC-PHE Centre for Environment and Health, King's College London, London WC2R 2LS, UK. volker.arlt@kcl.ac.uk. NIHR Health Protection Research Unit in Health Impact of Environmental Hazards at King's College London in Partnership with Public Health England, London WC2R 2LS, UK. volker.arlt@kcl.ac.uk.
700    1_
$a Stiborová, Marie $u Department of Biochemistry, Faculty of Science, Charles University, Albertov 2030, CZ-128 43 Prague 2, Czech Republic. stiborov@natur.cuni.cz.
773    0_
$w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 19, č. 1 (2018)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29304031 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20181008 $b ABA008
991    __
$a 20181010125403 $b ABA008
999    __
$a ok $b bmc $g 1340902 $s 1030401
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 19 $c 1 $e 20180105 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
LZP    __
$a Pubmed-20181008

Najít záznam

Citační ukazatele

Možnosti archivace